U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C22H26N2O2S.H2O4S
Molecular Weight 863.117
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ELETRIPTAN HEMISULFATE

SMILES

OS(O)(=O)=O.CN1CCC[C@@H]1CC2=CNC3=C2C=C(CCS(=O)(=O)C4=CC=CC=C4)C=C3.CN5CCC[C@@H]5CC6=CNC7=C6C=C(CCS(=O)(=O)C8=CC=CC=C8)C=C7

InChI

InChIKey=IYVZCNNIKYUHHM-WXMGBDCWSA-N
InChI=1S/2C22H26N2O2S.H2O4S/c2*1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20;1-5(2,3)4/h2*2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3;(H2,1,2,3,4)/t2*19-;/m11./s1

HIDE SMILES / InChI

Molecular Formula H2O4S
Molecular Weight 98.078
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C22H26N2O2S
Molecular Weight 382.519
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Eletriptan (eletriptan hydrobromide, trade name Relpax) is a selective 5-hydroxytryptamine (5-HT1B/1D) serotonin receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults. Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, and has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors. The therapeutic activity of eletriptan for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Eletriptan (Relpax) has been approved for use in the acute treatment of migraine in 51 countries and has been introduced in 17 countries including Mexico, Italy, France and Japan.

CNS Activity

Originator

Approval Year

PubMed

PubMed

TitleDatePubMed
Sumatriptan versus eletriptan: which is best?
2002 Dec
Current perspectives on effective migraine treatments: are small clinical differences important for patients?
2003
Newer formulations of the triptans: advances in migraine management.
2003
[Strong and sustained-acting triptan. Therewith migraine does not return soon].
2003 Aug 7
Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine.
2003 Dec
[Treatment of migraine: an update].
2003 Jan
Eletriptan issues.
2003 Jul-Aug
A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine.
2003 Jul-Aug
Cost-effectiveness of migraine treatment: a commentary.
2003 Jul-Aug
The evolving management of migraine.
2003 Jun
Safety profile of the triptans.
2003 Mar
[Highly selective beginning. Associated symptoms and side effects in retrospect].
2003 May 26
[Improved pharmacokinetics. Fast tryptan with sustained response].
2003 May 26
Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine.
2003 Nov
Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatory drugs.
2003 Oct
Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review.
2003 Oct
Musing on Mathew et al.
2003 Sep
Encapsulated sumatriptan is not bioequivalent to commercial sumatriptan.
2003 Sep
Unilateral time-delayed encapsulation does not make for a fair race.
2003 Sep
Migraine: diagnosis and management.
2003 Sep-Oct
Eletriptan for the short-term prophylaxis of cluster headache.
2004 Apr
Meta-analysis of oral triptans.
2004 Aug
New drugs 04, part 1.
2004 Feb
The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg.
2004 Feb
[Recent progress in therapy for migraine headache].
2004 Feb 10
[Use of triptanes according to indications. Risk of infarct is not increased].
2004 Feb 12
The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat.
2004 Feb 13
Neuronal expression and regulation of CGRP promoter activity following viral gene transfer into cultured trigeminal ganglia neurons.
2004 Jan 30
Gateways to clinical trials.
2004 Jan-Feb
Effect of high-dose intravenous eletriptan on coronary artery diameter.
2004 Jul
Cardiovascular safety of triptans.
2004 Jul
Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery.
2004 Jul
Nitrergic and glutamatergic neuronal mechanisms at the trigeminovascular first-order synapse.
2004 Jul
Gateways to clinical trials.
2004 Jul-Aug
Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms.
2004 Jun
Gateways to clinical trials.
2004 Mar
Eletriptan for the acute treatment of migraine: results of bridging a Japanese study to Western clinical trials.
2004 Mar
Cost considerations of acute migraine treatment.
2004 Mar
Effectiveness of eletriptan in acute migraine: primary care for Excedrin nonresponders.
2004 Mar
Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials.
2004 May
Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review.
2004 May
[A case of the usefulness of MR angiography and diffusion weighted image to evaluate migraine].
2004 Oct
[Spanish contribution to the clinical development of eletriptan: an analysis of controlled studies].
2004 Oct
No effect of eletriptan administration during the aura phase of migraine.
2004 Oct
[Meta-analysis of triptan treatment in migraine].
2004 Sep
[Triptans in migraine: from clinical view].
2004 Sep
[Triptans in migraine: a comparative review of pharmacology, pharmacokinetics].
2004 Sep
Gateways to clinical trials.
2004 Sep
Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project).
2004 Sep
TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management.
2004 Sep
Patents

Sample Use Guides

In Vivo Use Guide
The maximum recommended single dose of Relpax (eletriptan hydrobromide) is 40 mg. If after the initial dose, headache improves but then returns, a repeat dose may be beneficial. If a second dose is required, it should be taken at least 2 hours after the initial dose. If the initial dose is ineffective, controlled clinical trials have not shown a benefit of a second dose to treat the same attack. The maximum daily dose should not exceed 80 mg.
Route of Administration: Oral
In Vitro Use Guide
The 5-hydroxytryptamine (5-HT) receptor mediation of the contraction in guinea-pig iliac arteries moderately precontracted by prostaglandin F2alpha (PGF2alpha) was characterized in vitro using eletriptan. Eletriptan contracted guinea-pig iliac arteries and the concentration-response curve for eletriptan was biphasic (first phase: 0.01-3 uM, pD2 approximately 6.6; second phase: greater or equal 10 uM).
Substance Class Chemical
Created
by admin
on Tue Oct 22 16:44:19 UTC 2019
Edited
by admin
on Tue Oct 22 16:44:19 UTC 2019
Record UNII
AMM8PSU28B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ELETRIPTAN HEMISULFATE
Common Name English
Code System Code Type Description
PUBCHEM
9832589
Created by admin on Tue Oct 22 16:44:19 UTC 2019 , Edited by admin on Tue Oct 22 16:44:19 UTC 2019
PRIMARY
CAS
219790-71-3
Created by admin on Tue Oct 22 16:44:19 UTC 2019 , Edited by admin on Tue Oct 22 16:44:19 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY